Keenova Therapeutics plc Share-based Payment Arrangement, Expense
Keenova Therapeutics plc reported Share-based Payment Arrangement, Expense of $46.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-04-15
- Keenova Therapeutics plc share-based payment arrangement, expense for the quarter ending 2016-12-30 was $10.60M.
- Keenova Therapeutics plc share-based payment arrangement, expense for the quarter ending 2013-09-27 was $4.60M, a 64.29% increase year-over-year.
- Keenova Therapeutics plc share-based payment arrangement, expense for the quarter ending 2013-06-28 was $4.60M, a 76.92% increase year-over-year.
- Keenova Therapeutics plc share-based payment arrangement, expense for the quarter ending 2012-09-28 was $2.80M.
- Keenova Therapeutics plc share-based payment arrangement, expense for fiscal 2025 was $46.40M, a 544.44% increase from fiscal 2024.
- Keenova Therapeutics plc share-based payment arrangement, expense for fiscal 2024 was $7.20M.
- Keenova Therapeutics plc share-based payment arrangement, expense for fiscal 2021 was $10.20M, a 59.68% decline from fiscal 2020.
- Keenova Therapeutics plc share-based payment arrangement, expense for fiscal 2020 was $25.30M, a 25.15% decline from fiscal 2019.
| Period end | Share-based Payment Arrangement, Expense 1 month | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 5 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 10 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $46.40M 10-K · filed 2026-04-15 | |||||||
| 2024-12-27 | $7.20M 10-K · filed 2026-04-15 | |||||||
| 2023-12-29 | $0.00 10-K · filed 2026-04-15 | |||||||
| 2023-11-14 | $8.90M 10-K · filed 2026-04-15 | |||||||
| 2022-12-30 | $1.40M 10-K · filed 2025-03-13 | |||||||
| 2022-06-16 | $1.70M 10-K · filed 2025-03-13 | |||||||
| 2021-12-31 | $10.20M 10-K · filed 2024-03-26 | |||||||
| 2020-12-25 | $25.30M 10-K · filed 2023-03-03 | |||||||
| 2019-12-27 | $33.80M 10-K · filed 2022-03-15 | |||||||
| 2018-12-28 | $34.60M 10-K · filed 2021-03-10 | |||||||
| 2017-12-29 | $58.50M 10-K · filed 2020-02-26 | |||||||
| 2016-12-30 | $10.60M 10-K · filed 2019-02-26 | |||||||
| 2016-09-30 | $41.40M 10-K · filed 2019-02-26 | |||||||
| 2015-09-25 | $115.00M 10-K · filed 2018-02-27 | $116.10M 10-K · filed 2015-11-24 | ||||||
| 2014-09-26 | $64.90M 10-K · filed 2016-11-29 | $67.70M 10-K · filed 2014-11-25 | ||||||
| 2013-09-27 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-11-24 | $9.20M derived: sum of 2 quarters · filed 2015-11-24 | $16.00M 10-K · filed 2015-11-24 | $16.20M 10-K · filed 2013-12-13 | ||||
| 2013-06-28 | $4.60M 10-Q · filed 2013-08-12 | $11.40M 10-Q · filed 2013-08-12 | ||||||
| 2012-09-28 | $2.80M derived: 8-K 12 month − 10-Q 9 month · filed 2015-04-03 | $5.40M derived: sum of 2 quarters · filed 2015-04-03 | $11.10M 8-K · filed 2015-04-03 | |||||
| 2012-06-29 | $2.60M 10-Q · filed 2013-08-12 | $8.30M 10-Q · filed 2013-08-12 | ||||||
| 2011-09-30 | $10.60M 10-K · filed 2013-12-13 |